Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

NCT02172768 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Graft Versus Host Disease Grade II-IV
Allogeneic Stem Cell Transplant
Acute Myeloid Leucaemia
Myelo Dysplastic Syndrome

Interventions

OTHER: alternate dosing
OTHER: daily dosing
DRUG: micafungin

Sponsor

Radboud University Medical Center